Mineralys Therapeutics Inc [NASDAQ: MLYS] gained 42.21% on the last trading session, reaching $14.96 price per share at the time.
If compared to the average trading volume of 281.20K shares, MLYS reached a trading volume of 15190084 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Mineralys Therapeutics Inc [MLYS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MLYS shares is $35.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MLYS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Mineralys Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 10, 2024. While these analysts kept the previous recommendation, Goldman raised their target price to Buy. The new note on the price target was released on April 02, 2024, representing the official price target for Mineralys Therapeutics Inc stock. Previously, the target price had yet another raise to $27, while Wells Fargo analysts kept a Overweight rating on MLYS stock.
The Average True Range (ATR) for Mineralys Therapeutics Inc is set at 1.29 The Price to Book ratio for the last quarter was 3.90, with the Price to Cash per share for the same quarter was set at 3.98.
Trading performance analysis for MLYS stock
Mineralys Therapeutics Inc [MLYS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 67.34. With this latest performance, MLYS shares gained by 48.86% in over the last four-week period, additionally plugging by 25.29% over the last 6 months – not to mention a rise of 6.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MLYS stock in for the last two-week period is set at 76.56, with the RSI for the last a single of trading hit 83.85, and the three-weeks RSI is set at 70.44 for Mineralys Therapeutics Inc [MLYS]. The present Moving Average for the last 50 days of trading for this stock 10.47, while it was recorded at 11.19 for the last single week of trading, and 12.04 for the last 200 days.
Mineralys Therapeutics Inc [MLYS]: A deeper dive into fundamental analysis
Mineralys Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.02 and a Current Ratio set at 14.02.
Mineralys Therapeutics Inc [MLYS]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MLYS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mineralys Therapeutics Inc go to -3.25%.
An analysis of Institutional ownership at Mineralys Therapeutics Inc [MLYS]
The top three institutional holders of MLYS stocks are: CATALYS PACIFIC, LLC with ownership of 9.19 million shares, which is approximately 18.629%. SAMSARA BIOCAPITAL, LLC, holding 5.07 million shares of the stock with an approximate value of $$59.38 million in MLYS stocks shares; and SAMSARA BIOCAPITAL, LLC, currently with $$56.76 million in MLYS stock with ownership which is approximately 9.8285%.
